Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132)
Yan Shi(Institut des Maladies Métaboliques et Cardiovasculaires), Qi Wang(Sichuan University), Lori Kunselman(Bristol-Myers Squibb (United States)), Arvind Mathur(Bristol-Myers Squibb (United States)), Bang‐Chi Chen(Bristol-Myers Squibb (United States)), Robert A. Langish(Bristol-Myers Squibb (United States)), Leslie Leith(Bristol-Myers Squibb (United States)), Shiwei Tao(Bristol-Myers Squibb (Germany)), Dauh–Rurng Wu(Bristol-Myers Squibb (United States)), Michael K. Y. Wong(Bristol-Myers Squibb (United States)), Jovita Marcinkeviciene(Bristol-Myers Squibb (United States)), Robert Brigance(Bristol-Myers Squibb (United States)), Steven A. Spronk(Bristol-Myers Squibb (United States)), Helen G. Fuentes-Catanio(Bristol-Myers Squibb (United States)), Michael Cap, Carrie Xu, Sean Chen, Stephen Kalinowski(Bristol-Myers Squibb (United States)), Dawn Sun(Bristol-Myers Squibb (United States)), Bruce A. Ellsworth(Bristol-Myers Squibb (United States)), Ada Staal(Bristol-Myers Squibb (United States)), Wang Ying(Bristol-Myers Squibb (United States)), Wei Meng(Bristol-Myers Squibb (United States)), Denis E. Ryono(Institut des Maladies Métaboliques et Cardiovasculaires), Richard Sulsky(Bristol-Myers Squibb (Germany)), Hao Zhang(California Institute for Regenerative Medicine), Stanley R. Krystek(Collaborative Drug Discovery (United States)), Richard Rampulla(Bristol-Myers Squibb (United States)), Rebecca A. Smirk(Institut des Maladies Métaboliques et Cardiovasculaires), Joseph R. Taylor(Bristol-Myers Squibb (United States)), J.K. Muckelbauer(Institute of Crystallography), Gerry Everlof(Bristol-Myers Squibb (United States)), Jacob Zalaznick(Bristol-Myers Squibb (United States)), Lisa M. Kopcho(Bristol-Myers Squibb (United States)), Joseph A. Tino(Institut des Maladies Métaboliques et Cardiovasculaires), Rachel Zebo(Bristol-Myers Squibb (United States)), Xueqing Chen(Brigham and Women's Hospital), Yixin Li(Qinghai University), Aiying Wang(Bristol-Myers Squibb (United States)), K O'Malley(Beaumont Hospital), Yanou Yang(Bristol-Myers Squibb (United States)), Xiaohui Ma(Bristol-Myers Squibb (United States)), Beverly Jones(Bristol-Myers Squibb (United States)), Heng Liu(Bristol-Myers Squibb (United States)), Jung‐Hui Sun(DuPont (United States)), Scott A. Bolton(Institut des Maladies Métaboliques et Cardiovasculaires), Laura Nielsen(Bristol-Myers Squibb (United States)), Anuradha Gupta(Bristol-Myers Squibb (India)), Kristin N. Williams(Bristol-Myers Squibb (United States)), Joann Swartz(Bristol-Myers Squibb (United States))
Cited by 11
Related Papers
Mutation of the Stargardt Disease Gene ( <i>ABCR</i> ) in Age-Related Macular Degeneration
|Science|1997|878
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
|Nature|2007|732
MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products
|Bioorganic & Medicinal Chemistry Letters|1998|406
Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome
|Cell stem cell|2020|171
Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation
|Protein Science|2008|128